De-Extinction Tech Could Unlock Human Longevity Breakthroughs
Colossal Biosciences is reviving dire wolves and woolly mammoths — and the biotech spinoffs could reshape human healthcare.
Forget Jurassic Park fantasies. The real story behind de-extinction is what it means for your body, not just the ecosystem. Colossal Biosciences CEO Ben Lamm is making the case that bringing back species like the dire wolf and woolly mammoth is a gateway to breakthroughs in conservation, healthcare, and developmental biology.
Here's the trade worth watching: the gene-editing tools and cellular reprogramming techniques Colossal is building to resurrect extinct animals are the same fundamental technologies that could tackle age-related diseases in humans. You're essentially funding a moonshot R&D lab where the byproducts have massive medical upside.
Read more Tim Cook Steps Back as Apple Chair, Tells New CEO to Lead His Own Way →
Lamm argues the work isn't just about splashy headlines — it's about unlocking biological mechanisms that evolution buried millions of years ago. Woolly mammoths, for example, had cold-resistance adaptations and unique metabolic profiles that researchers believe could inform how we treat human conditions tied to cellular stress and aging.
Colossal sits at a rare intersection of conservation optics and deep biotech ambition. For investors and biotech watchers, this is a company that can pitch to environmentalists and pharmaceutical researchers in the same breath. That dual narrative is a fundraising superpower and a potential product pipeline — if the science delivers.
The big question isn't whether they can clone a mammoth. It's whether the genomic and cellular insights from doing so translate into therapies that reach humans. Lamm clearly believes they will. Continue reading at US Top News and Analysis.
